- $218.54m
- -$229.34m
- 35
- 47
- 45
- 38
Annual cashflow statement for Acelyrin, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS/A | PROSPECTUS/A | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | -41.8 | -64.8 | -382 | -248 |
| Depreciation | ||||
| Non-Cash Items | 25.2 | 3.32 | 160 | 21.2 |
| Unusual Items | ||||
| Purchased R&D | ||||
| Other Non-Cash Items | ||||
| Changes in Working Capital | 11.6 | -0.067 | 52.1 | -77.4 |
| Change in Prepaid Expenses | ||||
| Change in Accounts Payable | ||||
| Change in Accrued Expenses | ||||
| Other Operating Cash Flow | ||||
| Cash from Operating Activities | -4.98 | -61.5 | -170 | -304 |
| Capital Expenditures | — | — | -2.29 | -1.25 |
| Purchase of Fixed Assets | ||||
| Other Investing Cash Flow Items | -25 | -47.9 | -445 | 156 |
| Acquisition of Business | ||||
| Sale of Business | ||||
| Sale of Fixed Assets | ||||
| Sale/Maturity of Investment | ||||
| Purchase of Investments | ||||
| Other Investing Cash Flow | ||||
| Cash from Investing Activities | -25 | -47.9 | -448 | 155 |
| Financing Cash Flow Items | 0 | 10.3 | -8.32 | -1.94 |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Cash from Financing Activities | 125 | 274 | 568 | 5.39 |
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | 94.7 | 165 | -49 | -144 |